Natco Pharma [NATCOPHARM] vs Neuland Laboratories [NEULANDLAB] Detailed Stock Comparison
Natco Pharma
NSE
Loading...
Neuland Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Natco Pharma wins in 14 metrics, Neuland Laboratories wins in 6 metrics, with 0 ties. Natco Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Natco Pharma | Neuland Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 8.62 | 95.24 | Natco Pharma |
| Price-to-Book Ratio | 2.14 | 11.02 | Natco Pharma |
| Debt-to-Equity Ratio | 3.67 | 10.31 | Natco Pharma |
| PEG Ratio | 22.00 | -7.15 | Neuland Laboratories |
| EV/EBITDA | 6.21 | 71.92 | Natco Pharma |
| Profit Margin (TTM) | 42.57% | 13.24% | Natco Pharma |
| Operating Margin (TTM) | 36.84% | 4.88% | Natco Pharma |
| EBITDA Margin (TTM) | 36.84% | 4.88% | Natco Pharma |
| Return on Equity | 27.97% | 17.06% | Natco Pharma |
| Return on Assets (TTM) | 15.78% | 11.93% | Natco Pharma |
| Free Cash Flow (TTM) | $11.85B | $1.11B | Natco Pharma |
| Dividend Yield | 0.68% | 0.08% | Natco Pharma |
| 1-Year Return | -36.97% | 13.74% | Neuland Laboratories |
| Price-to-Sales Ratio (TTM) | 3.67 | 12.65 | Natco Pharma |
| Enterprise Value | $136.28B | $167.23B | Neuland Laboratories |
| EV/Revenue Ratio | 3.08 | 12.57 | Natco Pharma |
| Gross Profit Margin (TTM) | 79.59% | 47.77% | Natco Pharma |
| Revenue per Share (TTM) | $247 | $1,037 | Neuland Laboratories |
| Earnings per Share (Diluted) | $105.30 | $137.54 | Neuland Laboratories |
| Beta (Stock Volatility) | 0.19 | 0.03 | Neuland Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Natco Pharma vs Neuland Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Natco Pharma | -3.94% | -2.50% | -7.83% | 13.12% | -29.19% | -35.03% |
| Neuland Laboratories | 2.09% | 0.63% | 11.90% | 6.29% | -10.73% | -8.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Natco Pharma | -36.97% | 40.23% | 9.43% | 95.78% | 2,249.99% | 3,682.50% |
| Neuland Laboratories | 13.74% | 1,100.26% | 1,532.07% | 2,345.44% | 16,159.93% | 15,231.23% |
Performance & Financial Health Analysis: Natco Pharma vs Neuland Laboratories
| Metric | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹162.72B | ₹168.20B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 606,673 | 89,499 |
| 90 Day Avg. Volume | 1,444,085 | 134,149 |
| Last Close | ₹907.80 | ₹13,099.00 |
| 52 Week Range | ₹726.80 - ₹1,639.00 | ₹10,190.70 - ₹18,100.00 |
| % from 52W High | -44.61% | -27.63% |
| All-Time High | ₹1,639.00 (Sep 09, 2024) | ₹18,100.00 (Dec 02, 2024) |
| % from All-Time High | -44.61% | -27.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | -0.33% |
| Quarterly Earnings Growth | 0.05% | -0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.43% | 0.13% |
| Operating Margin (TTM) | 0.37% | 0.05% |
| Return on Equity (TTM) | 0.28% | 0.17% |
| Debt to Equity (MRQ) | 3.67 | 10.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹424.69 | ₹1,188.48 |
| Cash per Share (MRQ) | ₹162.87 | ₹186.76 |
| Operating Cash Flow (TTM) | ₹16.97B | ₹3.44B |
| Levered Free Cash Flow (TTM) | ₹8.90B | ₹2.60B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.68% | 0.08% |
| Last 12-Month Dividend | ₹6.00 | ₹12.00 |
Valuation & Enterprise Metrics Analysis: Natco Pharma vs Neuland Laboratories
| Metric | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 8.62 | 95.24 |
| Forward P/E | 22.00 | 35.34 |
| PEG Ratio | 22.00 | -7.15 |
| Price to Sales (TTM) | 3.67 | 12.65 |
| Price to Book (MRQ) | 2.14 | 11.02 |
| Market Capitalization | ||
| Market Capitalization | ₹162.72B | ₹168.20B |
| Enterprise Value | ₹136.28B | ₹167.23B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.08 | 12.57 |
| Enterprise to EBITDA | 6.21 | 71.92 |
| Risk & Other Metrics | ||
| Beta | 0.19 | 0.03 |
| Book Value per Share (MRQ) | ₹424.69 | ₹1,188.48 |
Financial Statements Comparison: Natco Pharma vs Neuland Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Revenue/Sales | ₹12.21B | ₹2.93B |
| Cost of Goods Sold | ₹2.49B | ₹1.53B |
| Gross Profit | ₹9.72B | ₹1.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹4.50B | ₹142.99M |
| EBITDA | ₹6.14B | ₹423.45M |
| Pre-Tax Income | ₹5.06B | ₹175.70M |
| Income Tax | ₹999.00M | ₹36.70M |
| Net Income (Profit) | ₹4.06B | ₹139.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Cash & Equivalents | ₹1.20B | ₹1.32B |
| Total Current Assets | ₹52.70B | ₹11.39B |
| Total Current Liabilities | ₹9.44B | ₹4.66B |
| Long-Term Debt | ₹46.00M | ₹1.09B |
| Total Shareholders Equity | ₹76.12B | ₹15.25B |
| Retained Earnings | N/A | ₹9.95B |
| Property, Plant & Equipment | ₹24.32B | ₹6.74B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 606,673 | 89,499 |
| Average Daily Volume (90 Day) | 1,444,085 | 134,149 |
| Shares Outstanding | 179.11M | 12.83M |
| Float Shares | 81.34M | 7.19M |
| % Held by Insiders | 0.51% | 0.38% |
| % Held by Institutions | 0.13% | 0.25% |
Dividend Analysis & Yield Comparison: Natco Pharma vs Neuland Laboratories
| Metric | NATCOPHARM | NEULANDLAB |
|---|---|---|
| Last 12-Month Dividend | ₹6.00 | ₹12.00 |
| Last 12-Month Dividend Yield | 0.68% | 0.08% |
| 3-Year Avg Annual Dividend | ₹7.00 | ₹12.00 |
| 3-Year Avg Dividend Yield | 0.28% | 0.20% |
| 3-Year Total Dividends | ₹21.00 | ₹36.00 |
| Ex-Dividend Date | Feb 18, 2025 | Jul 18, 2025 |